Inicia sesión Registrate Mi Biblioteca idioma

Idioma

biblioteca idioma abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará la selección de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por International Parkinson & Movement Disorder Society.

Enfermedad de Parkinson

2601 ARTíCULOS , VIENDO DEL 2491 AL 2505

PUBMED

Treatment of motor fluctuations in Parkinson's disease: recent developments and future directions.

Ramirez-Zamora A, Molho E.

Expert Rev Neurother. 2014 Jan;14(1):93-103. doi: 10.1586/14737175.2014.868306. Review.

0

0

0

PUBMED

Stereopsis impairment is associated with decreased color perception and worse motor performance in Parkinson's disease.

Sun L, Zhang H, Gu Z, Cao M, Li D, Chan P.

Eur J Med Res. 2014 May 24;19:29. doi: 10.1186/2047-783X-19-29.

0

0

0

PUBMED

Application of an OCT data-based mathematical model of the foveal pit in Parkinson disease.

Ding Y, Spund B, Glazman S, Shrier EM, Miri S, Selesnick I, Bodis-Wollner I.

J Neural Transm (Vienna). 2014 Nov;121(11):1367-76. doi: 10.1007/s00702-014-1214-2.

0

0

0

PUBMED

SNCA variants rs2736990 and rs356220 as risk factors for Parkinson's disease but not for amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population.

Guo XY, Chen YP, Song W, Zhao B, Cao B, Wei QQ, Ou RW, Yang Y, Yuan LX, Shang HF.

Neurobiol Aging. 2014 Dec;35(12):2882.e1-6. doi: 10.1016/j.neurobiolaging.2014.07.014.

0

0

0

PUBMED

Late stages of hematopoiesis and B cell lymphopoiesis are regulated by α-synuclein, a key player in Parkinson's disease.

Xiao W, Shameli A, Harding CV, Meyerson HJ, Maitta RW.

Immunobiology. 2014 Nov;219(11):836-44. doi: 10.1016/j.imbio.2014.07.014.

0

0

0

PUBMED

α-Synuclein ubiquitination and novel therapeutic targets for Parkinson's disease.

Rott R, Szargel R, Shani V, Bisharat S, Engelender S.

CNS Neurol Disord Drug Targets. 2014;13(4):630-7. Review.

0

0

0

PUBMED

Brain SPECT can differentiate between essential tremor and early-stage tremor-dominant Parkinson's disease.

Song IU, Park JW, Chung SW, Chung YA.

J Clin Neurosci. 2014 Sep;21(9):1533-7. doi: 10.1016/j.jocn.2013.11.035.

0

0

0

PUBMED

Neuroprotective effects of puerarin on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's disease model in mice.

Zhu G, Wang X, Wu S, Li X, Li Q.

Phytother Res. 2014 Feb;28(2):179-86. doi: 10.1002/ptr.4975.

0

0

0

PUBMED

Treatment and physiology in Parkinson's disease and dystonia: using transcranial magnetic stimulation to uncover the mechanisms of action.

Wagle Shukla A, Vaillancourt DE.

Curr Neurol Neurosci Rep. 2014 Jun;14(6):449. doi: 10.1007/s11910-014-0449-5. Review.

0

0

0

PUBMED

Motor output variability, deafferentation, and putative deficits in kinesthetic reafference in Parkinson's disease.

Torres EB, Cole J, Poizner H.

Front Hum Neurosci. 2014 Oct 21;8:823. doi: 10.3389/fnhum.2014.00823.

0

0

0

PUBMED

Mapping track density changes in nigrostriatal and extranigral pathways in Parkinson's disease.

Ziegler E, Rouillard M, André E, Coolen T, Stender J, Balteau E, Phillips C, Garraux G.

Neuroimage. 2014 Oct 1;99:498-508. doi: 10.1016/j.neuroimage.2014.06.033.

0

0

0

PUBMED

Neuroprotective Potential of Peroxisome Proliferator Activated Receptor- α Agonist in Cognitive Impairment in Parkinson's Disease: Behavioral, Biochemical, and PBPK Profile.

Uppalapati D, Das NR, Gangwal RP, Damre MV, Sangamwar AT, Sharma SS.

PPAR Res. 2014;2014:753587. doi: 10.1155/2014/753587.

0

0

0

Comentarios

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo HONcode Logo WIS

En colaboración con:

Zambon Neuroacademy